May. 13 at 1:23 PM
$FATE Fate (Current): ~
$280M Market Cap | 2028 Cash | Pivotal Trial H2 2026 | Off-the-Shelf, outpatient and FDA CDRP selection.
Peers: ~
$1.2B -
$2.0B Market Cap | Similar or far Behind Timelines | Autologous (Harder to scale). Standard CAR-T uses Fludarabine + Cyclophosphamide (Flu/Cy), which is highly toxic, requires a multi-day hospital stay, and wrecks the patient's immune system. Bendamustine is vastly milder. FATE states this conditioning allows for outpatient treatment.
$5 first stop and
$10 or M&A on the road. Hold strong, GOOOOOGO,
$FATE $ALLO $CABA $KYTX $LABU 🤑🤑🤑
